In a landmark breakthrough for modern medicine, the US Food and Drug Administration (FDA) has approved the first-ever gene therapy designed to treat genetic hearing loss. Developed by Regeneron Pharmaceuticals, the therapy - called Otarmeni - is being hailed as a transformative step toward restoring hearing in patients with inherited auditory conditions, and in a surprising move, the company has announced plans to provide the treatment free of cost for eligible patients.
Also read:Benjamin Netanyahu’s Prostate Cancer Diagnosis Sparks Global Alarm: Are Older Men Ignoring Silent Warning Signs?
Hearing loss affects over 430 million people worldwide, with a significant portion caused by genetic mutations. Until now, treatment options have largely been limited to hearing aids or cochlear implants, which assist hearing but do not address the underlying cause.
This newly approved gene therapy takes a radically different approach. Otarmeni is designed to treat a very rare form of inherited hearing loss caused by mutations in the OTOF gene, which affects roughly 50 babies born annually in the United States. The OTOF gene is responsible for producing otoferlin, a protein essential for transmitting sound signals from the inner ear to the brain. Without it, sound cannot be processed, resulting in profound deafness.
By targeting the defective gene responsible for hearing impairment, the treatment works at a cellular level to restore function in the inner ear. Early clinical trials have shown promising results, with some patients experiencing partial to significant recovery of hearing ability.
Till now, the treatment options have largely been limited to hearing aids or cochlear implants, which assist hearing but do not address the underlying cause
The therapy uses a modified viral vector to deliver a healthy copy of the faulty gene directly into the inner ear cells. Once inside, the corrected gene enables proper protein production, which is essential for converting sound waves into electrical signals that the brain can interpret.
Experts say this precision-based treatment represents a major advancement in genetic medicine, particularly for conditions that were previously considered irreversible.
In a move that has stunned both the medical community and patients alike, Regeneron has announced that it will offer the therapy at no cost to qualifying individuals, at least during the initial rollout phase. The company cited its commitment to accessibility and patient impact as key reasons behind the decision.
This initiative could remove one of the biggest barriers to cutting-edge treatments - cost. Gene therapies often carry price tags in the hundreds of thousands or even millions of dollars, making them inaccessible to many patients.
Source: India Latest News, Breaking News Today, Top News Headlines | Times Now
